Seminari di Ematologia Oncologica - Società Italiana di Ematologia

physiologic cells of the follicle mantle. Blood. 1994;
84: 403-7.
7. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller
TP, Grogan TM. A clinical analysis of two indolent lymphoma
entities: mantle cell lymphoma and marginal
zone lymphoma (including the mucosa-associated
lymphoid tissue and monocytoid B-cell subcategories):
a Southwest Oncology Group study. Blood.
1995; 85: 1075-82.
8. Palumbo GA, Parrinello N, Fargione G, Cardillo K,
Chiarenza A, Berretta S, et al. CD200 expression may
help in differential diagnosis between mantle cell lymphoma
and B-cell chronic lymphocytic leukemia. Leuk
Res. 2009; 33: 1212-6.
9. Orchard J, Garand R, Davis Z, Babbage G, Sahota
S, Matutes E, et al. A subset of t(11;14) lymphoma
with mantle cell features displays mutated IgVH genes
and includes patients with good prognosis, nonnodal
disease. Blood. 2003; 101: 4975-81.
10. Kienle D, Kröber A, Katzenberger T, Ott G, Leupolt
E, Barth TF, et al. VH mutation status and VDJ
rearrangement structure in mantle cell lymphoma: correlation
with genomic aberrations, clinical characteristics,
and outcome. Blood. 2003; 102: 3003-9.
11. Thelander EF, Rosenquist R. Molecular genetic characterization
reveals new subsets of mantle cell lymphoma.
Leuk Lymphoma. 2008; 49: 1042-9.
12. Hadzidimitriou A, Agathagelidis A, Murray F, Delfau-
Larue MH, Darzentas N, Navarro Lopez A, et al.
Sequence-Based evidence for antigen selection in
mantle cell lymphoma: remarkable immunoglobulin
gene repertoire biases, stereotyped antigen-binding
sites and recurrent hypermutations in certain subsets
(Abstract). Blood. 2009; 114: 1933.
13. Jares P, Colomer D, Campo E. Genetic and molecular
pathogenesis of mantle cell lymphoma: perspectives
for new targeted therapeutics. Nat Rev Cancer.
2007; 7: 750-62.
14. Rosenwald A, Wright G, Wiestner A, Chan WC,
Connors JM, Campo E, et al. The proliferation gene
expression signature is a quantitative integrator of
oncogenic events that predicts survival in mantle cell
lymphoma. Cancer Cell. 2003; 3: 185-97.
15. Fu K, Weisenburger DD, Greiner TC, Dave S, Wright
G, Rosenwald A, et al. Cyclin D1-negative mantle cell
lymphoma: a clinicopathologic study based on gene
expression profiling. Blood. 2005; 106: 4315-21.
16. Pinyol M, Hernandez L, Cazorla M, Balbín M, Jares
P, Fernandez PL, et al. Deletions and loss of expression
of p16INK4a and p21Waf1 genes are associated
with aggressive variants of mantle cell lymphomas.
Blood. 1997; 89: 272-80.
17. Hernández L, Beà S, Pinyol M, Ott G, Katzenberger
T, Rosenwald A, et al. CDK4 and MDM2 gene alterations
mainly occur in highly proliferative and aggressive
mantle cell lymphomas with wild-type INK4a/ARF
locus. Cancer Res. 2005; 65: 2199-206.
Linfoma mantellare
18. Stilgenbauer S, Winkler D, Ott G, Schaffner C, Leupolt
E, Bentz M, et al. Molecular characterization of 11q
deletions points to a pathogenic role of the ATM gene
in mantle cell lymphoma. Blood. 1999; 94: 3262-4.
19. Dal Col J, Zancai P, Terrin L, Guidoboni M, Ponzoni
M, Pavan A, et al. Distinct functional significance of
Akt and mTOR constitutive activation in mantle cell
lymphoma. Blood. 2008; 111: 5142-51.
20. Rizzatti EG, Falcão RP, Panepucci RA, Proto-Siqueira
R, Anselmo-Lima WT, Okamoto OK, et al. Gene
expression profiling of mantle cell lymphoma cells
reveals aberrant expression of genes from the PI3K-
AKT, WNT and TGFbeta signalling pathways. Br J
Haematol. 2005; 130: 516-26.
21. Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo
GR, et al. Essential role of stromally induced hedgehog
signaling in B-cell malignancies. Nat Med. 2007;
13: 944-51.
22. Fu L, Lin-Lee YC, Pham LV, Tamayo A, Yoshimura L,
Ford RJ. Constitutive NF-kappaB and NFAT activation
leads to stimulation of the BLyS survival pathway
in aggressive B-cell lymphomas. Blood. 2006;
107: 4540-8.
23. Fernàndez V, Salamero O, Espinet B, Solé F, Royo C,
Navarro A, et al. Genomic and gene expression profiling
defines indolent forms of mantle cell lymphoma.
Cancer Res. 2010; 70: 1408-18.
24. Velders GA, Kluin-Nelemans JC, De Boer CJ,
Hermans J, Noordijk EM, Schuuring E, et al. Mantlecell
lymphoma: a population-based clinical study. J
Clin Oncol. 1996; 14: 1269-74.
25. Argatoff LH, Connors JM, Klasa RJ, Horsman DE,
Gascoyne RD. Mantle cell lymphoma: a clinicopathologic
study of 80 cases. Blood. 1997; 89: 2067-78.
26. Schrader C, Meusers P, Brittinger G, Teymoortash A,
Siebmann JU, Janssen D, et al. Topoisomerase IIalpha
expression in mantle cell lymphoma: a marker of cell
proliferation and a prognostic factor for clinical outcome.
Leukemia. 2004; 18: 1200-6.
27. Bosch F, López-Guillermo A, Campo E, Ribera JM,
Conde E, Piris MA, et al. Mantle cell lymphoma: presenting
features, response to therapy, and prognostic
factors. Cancer. 1998; 82: 567-75.
28. Samaha H, Dumontet C, Ketterer N, Moullet I,
Thieblemont C, Bouafia F, et al. Mantle cell lymphoma:
a retrospective study of 121 cases. Leukemia. 1998;
12: 1281-7.
29. Tiemann M, Schrader C, Klapper W, Dreyling MH,
Campo E, Norton A, et al. Histopathology, cell proliferation
indices and clinical outcome in 304 patients
with mantle cell lymphoma (MCL): a clinicopathological
study from the European MCL Network. Br J
Haematol. 2005; 131: 29-38.
30. No authors listed. A predictive model for aggressive
non-Hodgkin’s lymphoma. The International Non-
Hodgkin’s Lymphoma Prognostic Factors Project. N
Engl J Med. 1993; 329: 987-94.
41